Other
Magnetic Resonance Imaging
1
Pipeline Programs↗
9
Active Trials↗
8
Companies Involved↗
Magnetic Resonance Imaging is an early-stage landscape with 1 program across 8 companies. The most active players are Pfizer, Eli Lilly, Bayer.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Analysis
Trial Status
67
clinical trials
Completed38 · 57%
Unknown status8 · 12%
Terminated8 · 12%
Recruiting7 · 10%
Withdrawn4 · 6%
Not yet recruiting1 · 1%
Other1 · 1%
Clinical Trials
Trial Activity
67 trials
Evaluation of 18F-Fluciclovine Positron Emission Tomography - Magnetic Resonance Imaging (PET-MRI) in LGG
Recruiting·—·Phase 1·NCT05555550·30 enrolled
Propofol-Only Versus Dexmedetomidine-Propofol in Children Undergoing Magnetic Resonance Imaging
Not yet recruiting·—·Phase 4·NCT07369128·105 enrolled
A Pilot Study of Dexmedetomidine-Propofol in Children Undergoing Magnetic Resonance Imaging
Completed·—·Phase 4·NCT02633241·71 enrolled
Efficacy of Propofol-Ketamine and Sevoflurane in Children Undergoing Magnetic Resonance Imaging
Completed·—·N/A·NCT06832683·230 enrolled
Resuvastatin Treatment for Symptomatic Middle Cerebral Artery Stenosis Based on High-resolution Magnetic Resonance Imaging
Completed·—·Phase 4·NCT02041117·162 enrolled
Page 1 of 5
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)